TPT1

Across TCGA pan-cancer cohorts, TPT1 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of TPT1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where TPT1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TPT1 is over-expressed in tumor, although a few such as BLCA and LUSC show the opposite, repressed pattern.

KIRC, BLCA, and LUSC are the cancer types where TPT1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TPT1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+0.790	<.001	12	view →
BLCA	All	All	−0.621	<.001	11	view →
LUSC	Female	All	−1.052	<.001	8	view →
HNSC	Male	All	−0.560	<.001	8	view →
KICH	Female	II,III,IV	−1.862	<.001	6	view →
UCEC	All	All	−0.800	<.001	6	view →
LUAD	All	III,IV	−0.772	.001	6	view →
BRCA	All	II,III,IV	−0.585	<.001	6	view →
THCA	All	All	+0.242	<.001	6	view →
COAD	All	II,III,IV	+0.346	.012	3	view →
LIHC	All	All	−0.236	.017	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

TPT1–KIRC

Open the KIRC breakdown →